Management of Chronic Liver Disease

Introduction to Chronic Liver Disease Management

The management of chronic liver disease requires treating the underlying etiology to prevent progression to cirrhosis and hepatocellular carcinoma, implementing surveillance protocols once cirrhosis develops, and managing complications through lifestyle modifications, vaccinations, and monitoring for portal hypertension sequelae, as recommended by the European Association for the Study of the Liver 1, 2

Antiviral therapy for chronic hepatitis B and C is essential - sustained HBV suppression and HCV sustained viral response prevent progression to cirrhosis and reduce (but do not eliminate) HCC risk, according to the American Association for the Study of Liver Diseases 3, 1
Complete alcohol abstinence is mandatory - heavy drinking (>4 drinks/day or >14 drinks/week in men; >3 drinks/day or >7 drinks/week in women) must be avoided, as stated by the National Institute on Alcohol Abuse and Alcoholism 4
Weight loss of 5-7% improves steatohepatitis; ≥10% may improve fibrosis, as recommended by the American Gastroenterological Association 4

Hepatitis B vaccination for all infants (universal childhood immunization), high-risk adults, and exposed individuals, as recommended by the Centers for Disease Control and Prevention 2, 5
Hepatitis A vaccination for all anti-HAV negative patients with chronic liver disease, according to the American Association for the Study of Liver Diseases 1
Coffee consumption should be encouraged - decreases HCC risk in patients with chronic liver disease, as suggested by the European Association for the Study of the Liver 3

Biochemical markers: AST, ALT, GGT, alkaline phosphatase, bilirubin, albumin, globulins, complete blood count, prothrombin time, as recommended by the American Association for the Study of Liver Diseases 1
Hepatic ultrasound, as suggested by the European Association for the Study of the Liver 1
6-monthly ultrasound and AFP measurement for all cirrhotic patients, as recommended by the American Association for the Study of Liver Diseases 2

All patients with cirrhosis or severe cholestasis (bilirubin >3× upper limit for >6 months) require bone density assessment, according to the National Institutes of Health 6, 8
Calcium supplementation (1-1.2 g/day) plus vitamin D₃ (400-800 IU/day) for all cholestatic patients, as recommended by the American Gastroenterological Association 7, 6
Statins can be safely used to treat dyslipidemia in NAFLD/NASH patients - no increased risk of serious liver injury, as stated by the American Association for the Study of Liver Diseases 4